Table of Contents
| << Previous Issue | Feb 2013 (Vol: 2013, Issue: 2) | Next Issue >> |
- Section: Licensing
-
Avalon Ventures’ Afraxis Licenses Entire Drug Portfolio to Genentech
-
The Medicines Company Licenses Alnylam’s RNAi Programme Targeting PCSK9
-
Opexa Therapeutics Grants Merck Serono Option to Multiple Sclerosis T-cell Therapy
-
Reckitt Benckiser Licenses Seven OTC Brands from BMS in Latin America
-
Biocon Finds a New Partner for its Biosimilar Insulin Analogues in Mylan
-
Roche Licenses Chiasma’s Late-Stage Oral Acromegaly Therapy
- Section: Mergers & Acquisitions
-
Baxter Buys Late-Stage Haemophilia Drug OBI-1 from Ipsen and Troubled Inspiration Biopharmaceuticals
-
Actavis Expands in Women’s Health with Uteron Pharma Purchase
-
Biogen Idec Buys Complete Ownership of Tysabri® from Elan
-
Eisai Divests US Rights to CTCL Therapy Targretin® to Valeant
- Section: Opinion & Analysis
-
A Review of Deal Making in 2012
- Section: Research & Development
-
AstraZeneca to Evaluate Orexo Respiratory Programme Previously Partnered with Janssen
-
Lycera and Merck & Co. Form Second Autoimmune Disease Collaboration
-
Merck & Co. Changes Tack on Biosimilars with Samsung Bioepis Collaboration
RSS